It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARDX’s FA Score shows that 0 FA rating(s) are green whileBCRX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARDX’s TA Score shows that 4 TA indicator(s) are bullish while BCRX’s TA Score has 4 bullish TA indicator(s).
ARDX (@Biotechnology) experienced а -3.34% price change this week, while BCRX (@Biotechnology) price change was +4.53% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.87%. For the same industry, the average monthly price growth was -2.14%, and the average quarterly price growth was +8.61%.
ARDX is expected to report earnings on Mar 05, 2025.
BCRX is expected to report earnings on Feb 19, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ARDX | BCRX | ARDX / BCRX | |
Capitalization | 1.3B | 1.62B | 80% |
EBITDA | -53.06M | -24.12M | 220% |
Gain YTD | -11.290 | 30.885 | -37% |
P/E Ratio | N/A | N/A | - |
Revenue | 252M | 413M | 61% |
Total Cash | 190M | 330M | 58% |
Total Debt | 104M | 809M | 13% |
ARDX | BCRX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 65 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 61 | |
P/E GROWTH RATING 1..100 | 57 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (3) in the Biotechnology industry is significantly better than the same rating for ARDX (98). This means that BCRX’s stock grew significantly faster than ARDX’s over the last 12 months.
BCRX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for ARDX (100). This means that BCRX’s stock grew somewhat faster than ARDX’s over the last 12 months.
ARDX's SMR Rating (97) in the Biotechnology industry is in the same range as BCRX (100). This means that ARDX’s stock grew similarly to BCRX’s over the last 12 months.
BCRX's Price Growth Rating (61) in the Biotechnology industry is in the same range as ARDX (62). This means that BCRX’s stock grew similarly to ARDX’s over the last 12 months.
ARDX's P/E Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for BCRX (100). This means that ARDX’s stock grew somewhat faster than BCRX’s over the last 12 months.
ARDX | BCRX | |
---|---|---|
RSI ODDS (%) | 3 days ago83% | N/A |
Stochastic ODDS (%) | 3 days ago87% | 3 days ago78% |
Momentum ODDS (%) | 3 days ago85% | 3 days ago86% |
MACD ODDS (%) | 3 days ago83% | 3 days ago79% |
TrendWeek ODDS (%) | 3 days ago83% | 3 days ago82% |
TrendMonth ODDS (%) | 3 days ago83% | 3 days ago84% |
Advances ODDS (%) | 10 days ago86% | 10 days ago81% |
Declines ODDS (%) | 4 days ago81% | 4 days ago80% |
BollingerBands ODDS (%) | 3 days ago90% | 3 days ago73% |
Aroon ODDS (%) | 3 days ago85% | N/A |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MINFX | 37.48 | 0.25 | +0.67% |
MFS International Intrinsic Value R2 | |||
FBPEX | 28.99 | 0.01 | +0.03% |
Cantor Fitzgerald Equity Div Plus Inst | |||
CMUAX | 15.31 | -0.06 | -0.39% |
Columbia Select Mid Cap Value A | |||
BRUDX | 17.92 | -0.09 | -0.50% |
MFS Blended Research Value Equity A | |||
HIMCX | 30.79 | -0.26 | -0.84% |
Hartford MidCap HLS IA |
A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.
Ticker / NAME | Correlation To ARDX | 1D Price Change % | ||
---|---|---|---|---|
ARDX | 100% | -1.43% | ||
VCYT - ARDX | 45% Loosely correlated | -2.84% | ||
HRTX - ARDX | 41% Loosely correlated | +4.88% | ||
PTGX - ARDX | 40% Loosely correlated | +2.71% | ||
NKTX - ARDX | 39% Loosely correlated | -2.94% | ||
BCRX - ARDX | 39% Loosely correlated | +6.96% | ||
More |
A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with PGEN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then PGEN could also see price increases.
Ticker / NAME | Correlation To BCRX | 1D Price Change % | ||
---|---|---|---|---|
BCRX | 100% | +6.96% | ||
PGEN - BCRX | 47% Loosely correlated | -3.96% | ||
VCYT - BCRX | 46% Loosely correlated | -2.84% | ||
NKTX - BCRX | 45% Loosely correlated | -2.94% | ||
INZY - BCRX | 41% Loosely correlated | -7.81% | ||
BEAM - BCRX | 41% Loosely correlated | -2.69% | ||
More |